Telix Granted FDA Approval for ZIRCON Renal Cancer Imaging
Filed with ASX · · 1 page · English
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- NDA Clinical Briefing Package Submitted to the US FDA
- Zircon P3 IND submitted to US FDA
- Telix and Vic Cancer Centre receive Cancer Australia grant
- Telix and ATONCO Partner for Bladder Cancer
- Telix and AusHealth Partner for Lung, Ovarian Cancer
Later from Telix Pharmaceuticals
- Appendix 4C - December 2019 Quarter
- Appendix 4E - Summary of Results
- Positive FDA feedback on NDA submission process
- Telix and partners receive 500k CRC research grant
- Telix completes acquisition of licensed production facility
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals